③ Business Expansion Targets IPO Momentum Next February with aRPM Technology Flagship “HiCardi”

[DealSite Reporter Da-eun Lee]

“Now is the time for a Korean medical device company to compete with global big tech. From Wonju—not Seoul—we will challenge the global market and build a company worth at least one-tenth of U.S. medical device giant Medtronic.”

Jung-hwan Park, CEO of Mezoo, made the remarks in an interview with DealSite on the 24th at the company’s headquarters in Wonju, Gangwon Province. Mezoo is a medical device manufacturer developing wearable patches, ultra-miniaturized biosensors, and AI-based real-time biosignal measurement (aRPM) technologies. Its flagship product is “HiCardi,” a platform that enables remote, real-time monitoring of patients’ vital signs.

Although Park is originally from Sacheon, South Gyeongsang Province, his connection to Wonju began when he entered the Department of Biomedical Engineering at Yonsei University Wonju Campus. At the time, the department—led by Professor Hyung-ro Yoon—was Asia’s first medical device program and served as the starting point for establishing Wonju as a specialized medical device hub.

Park recalled that choosing Wonju over Seoul was a simple decision because it was home to Asia’s first medical device department. He added that while domestic medical device development once focused on imitating foreign equipment, he believed that combining Korea’s emerging wireless infrastructure with medical devices would open a new path forward.